Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V A Saunders

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Letters in Applied Microbiology|September 1, 1996
Potential chitinase activating factor from yeast cells of Candida albicansD J Jackson, V A Saunders, A M Humphreys
Nucleic Acids Research|November 25, 1986
Deletion and rearrangement of plasmid DNA during transformation of Escherichia coli with linear plasmid moleculesE C Conley, V A Saunders, J R Saunders
Nucleic Acids Research|November 25, 1986
Mechanism of intramolecular recyclization and deletion formation following transformation of Escherichia coli with linearized plasmid DNAE C Conley, V A Saunders, V Jackson, et al.
Biochimica Et Biophysica Acta|April 5, 1973
Kinetic and thermodynamic properties of membrane-bound cytochromes of aerobically and photosynthetically grown Rhodopseudomonas spheroidesJ L Connelly, O T Jones, V A Saunders, et al.
Leukemia|September 3, 2010
OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1D L White, V A Saunders, P Dang, et al.
Leukemia|February 14, 2015
Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cellsL Lu, V A Saunders, T M Leclercq, et al.
Leukemia|November 21, 2012
Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cellsD L White, L N Eadie, V A Saunders, et al.
Leukemia|March 6, 2009
Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cellsD K Hiwase, D L White, V A Saunders, et al.
Leukemia|February 12, 2010
Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activityJ R Engler, A Frede, V A Saunders, et al.
Leukemia|July 16, 2016
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatmentL N Eadie, P Dang, V A Saunders, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Letters in Applied Microbiology|September 1, 1996
Potential chitinase activating factor from yeast cells of Candida albicansD J Jackson, V A Saunders, A M Humphreys
Nucleic Acids Research|November 25, 1986
Deletion and rearrangement of plasmid DNA during transformation of Escherichia coli with linear plasmid moleculesE C Conley, V A Saunders, J R Saunders
Nucleic Acids Research|November 25, 1986
Mechanism of intramolecular recyclization and deletion formation following transformation of Escherichia coli with linearized plasmid DNAE C Conley, V A Saunders, V Jackson, et al.
Biochimica Et Biophysica Acta|April 5, 1973
Kinetic and thermodynamic properties of membrane-bound cytochromes of aerobically and photosynthetically grown Rhodopseudomonas spheroidesJ L Connelly, O T Jones, V A Saunders, et al.
Leukemia|September 3, 2010
OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1D L White, V A Saunders, P Dang, et al.
Leukemia|February 14, 2015
Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cellsL Lu, V A Saunders, T M Leclercq, et al.
Leukemia|November 21, 2012
Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cellsD L White, L N Eadie, V A Saunders, et al.
Leukemia|March 6, 2009
Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cellsD K Hiwase, D L White, V A Saunders, et al.
Leukemia|February 12, 2010
Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activityJ R Engler, A Frede, V A Saunders, et al.
Leukemia|July 16, 2016
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatmentL N Eadie, P Dang, V A Saunders, et al.
Pageof 4